Weekly update Companies AI-cruiter Recruiting

Day One Biopharmaceuticals

Founded: 2018

Location: South SF, CA

Employee range: 11 - 50

Clinical stage: Clin2

Therapy area: Pediatric glioma

Drug types: ONC, PED

Lead product: Tovorafenib

Product link: https://www.dayonebio.com/our-pipeline/

Funding: $172.5M stock Jun 2023; $150M stock Jun 2022; $184M IPO May 2021; $130M B Feb 2021; $60M A May 2020

dayonebio.com

linkedin.com

job board

Short description:

Cancer Treatments

Drug notes:

Also additional Clin2 pediatric glioma, Clin1 solid tumors; Pimasertib Clin1 solid tumors

Long description:

Day One Biopharmaceuticals is developing therapies for patients of all ages with life-threatening diseases. The most common childhood brain cancer is pediatric low-grade glioma (pLGG), and it currently lacks effective cures. Through partnering with leading clinical oncologists, families and scientists, Day One is identifying, acquiring and developing cancer treatments. Day One’s lead product, DAY101 (tovorafenib), is in Phase 1/2 clinical trials for treatment against pLGG. DAY101 is an orally-taken, brain-penetrant pan-RAF inhibitor. Day One’s pipeline also includes pimasertib, a small molecule inhibitor of MEK-1/-2.